Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.81 |
| ▸ | MITF | O75030 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.65 |
| ▸ | TUBB | P07437 | 4/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238159 | 1.00 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL4320572 | 0.92 | TUBB4A (0.77) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL4425550 | 0.89 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL4326091 | 0.88 | ALDH1A1 (0.64) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL4427815 | 0.87 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL4320545 | 0.85 | TUBB4A (0.86) | SMN1; SMN2NPC1MITFHTTRAB9A | |
| SCHEMBL5959381 | 0.85 | ALDH1A1 (0.60) | SMN1; SMN2NPC1MITFHTTKDM4E | |
| SCHEMBL5959417 | 0.85 | KDM4E (0.60) | SMN1; SMN2NPC1HTTKDM4EALDH1A1 | |
| SCHEMBL5959439 | 0.84 | MEN1 (0.67) | SMN1; SMN2NPC1HTTKDM4EALDH1A1 | |
| SCHEMBL31237204 | 0.84 | MAPK1 (0.65) | SMN1; SMN2NPC1HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | claimed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | claimed |
| US-7507762-B2 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7053117-B2 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| EP-1392683-A4 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6906203-B1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1392683-A1 | SUBSTITUTED 4 i H /i -CHROMENES AND ANALOGS AS ACTIVATORS OFGASP ASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1230232-B1 | SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002092594-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154015-A1 | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, CASP5 | SMN1; SMN2 4107/4885NPC1 3666/4885MITF 382/4885 |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP10 | SMN1; SMN2 3885/4885NPC1 3560/4885MITF 298/4885 |
| US-20060035925-A1 | SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP4, CASP3, CASP7 | SMN1; SMN2 3907/4885NPC1 3790/4885MITF 538/4885 |
| US-20030065018-A1 | Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP5, CASP1 | SMN1; SMN2 3893/4885NPC1 2578/4885MITF 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.